Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2023-11-01 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
关于回购股份进展情况的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the progress of its share repurchase program. It details the board approval of the share buyback plan, the repurchase price limits, the repurchase period, and the actual shares repurchased to date with prices and amounts paid. The document does not contain full financial statements or comprehensive financial analysis but reports on the status of the company's own share transactions. This fits the definition of 'Transaction in Own Shares' (POS), which covers reports of the company buying back or selling its own shares (share repurchase/issuance). The document length is short and focused solely on the share repurchase progress, confirming it is not a full financial report or an announcement of a report publication. Therefore, the correct classification is POS with high confidence.
2023-11-01 Chinese
关于以集中竞价交易方式首次回购股份的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the company's first share repurchase through centralized bidding. It details the number of shares repurchased, prices, total amount paid, and references the company's share repurchase plan and related prior announcements. There is no financial report or detailed financial data presented, only a disclosure of a transaction in own shares. This fits the category of a share repurchase announcement rather than a full financial report or other types of filings.
2023-10-26 Chinese
关于全资子公司向实际控制人租用办公用房的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a related-party transaction where the company's wholly-owned subsidiary leases office space from the company's actual controller. It details the transaction terms, approval by the board, independent director opinions, and compliance with listing rules. There is no financial report or earnings data presented. The document is a formal disclosure of a related-party transaction, which fits best under Regulatory Filings (RNS) as it is a compliance announcement and does not match other specific categories like capital updates or management changes.
2023-10-20 Chinese
第四届董事会第十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from Lingkang Pharmaceutical Group Co., Ltd. It details the convening and decisions of the fourth board's tenth meeting, including approval of the 2023 third quarter report and another agenda item. The document references the full third quarter report being available on the Shanghai Stock Exchange website, indicating this document itself is not the report but an announcement of board resolutions. The content focuses on board meeting details and voting results, fitting the category of Board/Management Information (MANG). The document length is short (741 characters), consistent with an announcement rather than a full report.
2023-10-20 Chinese
独立董事关于第四届董事会第十次会议拟审议的关联交易事项事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors regarding a related-party transaction to be reviewed at a board meeting. It references governance rules and confirms the fairness and reasonableness of the transaction. The content is focused on board-level approval and governance matters rather than financial results, audit, or shareholder voting outcomes. It is not a full report, earnings release, or regulatory filing but rather a governance-related opinion on a specific agenda item. Therefore, it fits best under Board/Management Information (MANG). The document length is short and specific to management/board information, not a report or announcement of a report.
2023-10-20 Chinese
2023年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023 年第三季度报告' which translates to '2023 Third Quarter Report'. It contains detailed financial data including income statement, balance sheet, cash flow statement, and notes for the third quarter period ending September 30, 2023. The report is unaudited as indicated. The content includes comprehensive financial figures and analysis for a period shorter than a full fiscal year, consistent with an interim or quarterly report. There is no indication that this is an announcement of a report or a certification document. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2023
2023-10-20 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.